Allarity Therapeutics Receives Nasdaq-Approved Extension to Regain Compliance With Nasdaq Listing Rule 5550(B)(1)
Alarity Therapeutics獲得納斯達克批准的延期,以恢復對納斯達克上市規則5550(B)(1)的遵守
Allarity Therapeutics Receives Nasdaq-Approved Extension to Regain Compliance With Nasdaq Listing Rule 5550(B)(1)
Alarity Therapeutics獲得納斯達克批准的延期,以恢復對納斯達克上市規則5550(B)(1)的遵守
使用瀏覽器的分享功能,分享給你的好友吧